Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Jazz Pharmaceuticals JAZZ in the last three months.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 7 5 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 2 2 0 0 0
3M Ago 4 3 0 0 0

Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $198.25, a high estimate of $230.00, and a low estimate of $169.00. A decline of 0.88% from the prior average price target is evident in the current average.

price target chart

Deciphering Analyst Ratings: An In-Depth Analysis

A clear picture of Jazz Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Madhu Kumar Goldman Sachs Announces Buy $169.00 -
Oren Livnat HC Wainwright & Co. Maintains Buy $200.00 -
Balaji Prasad Barclays Lowers Overweight $200.00 $230.00
Ami Fadia Needham Maintains Buy $222.00 -
Charles Duncan Cantor Fitzgerald Maintains Overweight $180.00 -
Jessica Fye JP Morgan Raises Overweight $190.00 $170.00
Charles Duncan Cantor Fitzgerald Maintains Overweight $180.00 -
Joon Lee Truist Securities Maintains Buy $200.00 -
David Amsellem Piper Sandler Raises Overweight $188.00 $171.00
Ami Fadia Needham Maintains Buy $220.00 -
Annabel Samimy Stifel Raises Buy $230.00 $225.00
Oren Livnat HC Wainwright & Co. Lowers Buy $200.00 $204.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Jazz Pharmaceuticals analyst ratings.

Delving into Jazz Pharmaceuticals's Background

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals: A Financial Overview

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 1.03%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Jazz Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.62%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Jazz Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.39%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Jazz Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.13%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.57, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!